Targeting the urokinase plasminogen activator pathway inhibits pancreatic cancer progression

被引：0
|
作者：
Hosen, S. M. Z. [1 ,2 ]
Haar, J. [1 ,2 ]
Xu, Z. [1 ,2 ]
Perera, C. [1 ,2 ]
Mekapogu, A. R. [1 ,2 ]
Pang, T. C. Y. [1 ,2 ]
Pothula, S. [1 ,2 ]
Goldstein, D. [1 ]
Pirola, R. [1 ]
Wilson, J. [1 ]
Buckley, B. J. [3 ,4 ,5 ]
Ranson, M. [3 ,4 ,5 ]
Apte, M. [1 ,2 ]
机构：
[1] Univ New South Wales, Pancreat Res Grp, South Western Sydney Clin Sch, Fac Med, Sydney, NSW, Australia
[2] Ingham Inst Appl Med Res, Sydney, NSW, Australia
[3] Univ Wollongong, Mol Horizons, Fac Sci Med & Hlth, Wollongong, NSW, Australia
[4] Univ Wollongong, Sch Chem & Mol Biosci, Fac Sci Med & Hlth, Wollongong, NSW, Australia
[5] Illawarra Hlth & Med Res Inst, Wollongong, NSW, Australia
来源：
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY | 2021年 / 36卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
219
引用
收藏
页码：25 / 26
页数：2
相关论文
共 50 条
  • [41] Enhanced expression of urokinase plasminogen activator and its receptor in pancreatic carcinoma
    Cantero, D
    Friess, H
    Deflorin, J
    Zimmermann, A
    Brundler, MA
    Riesle, E
    Korc, M
    Buchler, MW
    BRITISH JOURNAL OF CANCER, 1997, 75 (03) : 388 - 395
  • [42] Enhanced expression of urokinase plasminogen activator and its receptor in pancreatic carcinoma
    D Cantero
    H Friess
    J Deflorin
    A Zimmermann
    M-A Bründler
    E Riesle
    M Korc
    MW Büchler
    British Journal of Cancer, 1997, 75 : 388 - 395
  • [43] Urokinase-type plasminogen activator inhibits amyloid-β neurotoxicity and fibrillogenesis via plasminogen
    Tucker, HM
    Kihiko-Ehmann, M
    Estus, S
    JOURNAL OF NEUROSCIENCE RESEARCH, 2002, 70 (02) : 249 - 255
  • [44] LIMITED ACTIVATION OF PLASMINOGEN BY UROKINASE AND PLASMINOGEN ACTIVATOR
    BOBBITT, JL
    CLAVIN, SA
    FEDERATION PROCEEDINGS, 1976, 35 (07) : 1706 - 1706
  • [45] Association of urokinase-type plasminogen activator and its inhibitor with disease progression and prognosis in ovarian cancer
    Konecny, G
    Untch, M
    Pihan, A
    Kimmig, R
    Gropp, M
    Stieber, P
    Hepp, H
    Slamon, D
    Pegram, M
    CLINICAL CANCER RESEARCH, 2001, 7 (06) : 1743 - 1749
  • [46] ELEVATION OF UROKINASE-TYPE PLASMINOGEN-ACTIVATOR DURING PROGRESSION AND METASTASIS IN COLORECTAL-CANCER
    TANAKA, T
    KONNO, H
    NISHINO, N
    BABA, S
    URANO, T
    TAKADA, Y
    TAKADA, A
    THROMBOSIS AND HAEMOSTASIS, 1993, 69 (06) : 1038 - 1038
  • [47] Targeting of tissue plasminogen activator to the regulated pathway of secretion
    Parmer, RJ
    Miles, LA
    TRENDS IN CARDIOVASCULAR MEDICINE, 1998, 8 (07) : 306 - 312
  • [48] Positron emission computed tomography targeting urokinase plasminogen activator receptor (uPAR) in cancer: a systematic review
    Camedda, Riccardo
    Frantellizzi, Viviana
    Danieli, Roberta
    De Vincentis, Giuseppe
    Filippi, Luca
    EXPERT REVIEW OF ANTICANCER THERAPY, 2024, 24 (3-4) : 137 - 145
  • [49] Targeting the Urokinase Plasminogen Activator Receptor With a Monoclonal Antibody Impairs the Growth of Human Colorectal Cancer in the Liver
    Van Buren, George, II
    Gray, Michael J.
    Dallas, Nikolaos A.
    Xia, Ling
    Lim, Sherry J.
    Fan, Fan
    Mazar, Andrew P.
    Ellis, Lee M.
    CANCER, 2009, 115 (14) : 3360 - 3368
  • [50] Prognostic value of urokinase plasminogen activator and plasminogen activator inhibitor-1 in renal cell cancer
    Hofmann, R
    Lehmer, A
    Hartung, R
    Robrecht, C
    Buresch, M
    Grothe, F
    JOURNAL OF UROLOGY, 1996, 155 (03): : 858 - 862
12345